Clinical Validation of Immunovia Next-Generation Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer

Completed

• Conditions: Pancreatic Cancer Stage I; Pancreatic Cancer Stage II; Cancer Diagnosis; PDAC - Pancreatic Ductal Adenocarcinoma

• Registration Number: NCT06947382
• Lead Sponsor: Immunovia, Inc.

Brief Summary

This is a case-control study to clinically validate the performance of a protein biomarker test to differentiate Stage I and Stage II pancreatic ductal adenocarcinoma (PDAC) patient samples from samples acquired from control patients not diagnosed with PDAC but at increased risk of disease due to familial/genetic history or clinical symptoms.

Detailed Description

This case-control study is being conducted to determine the performance of a multiplex protein biomarker model in human serum samples.

Serum samples were collected for analysis from patients with Stages I and II pancreatic ductal adenocarcinoma (PDAC) and non-PDAC controls of similar demographics who were at increased risk of PDAC because their familial or genetic history or clinical symptoms. Investigators and patients will not receive individual patient results, therefore patient care will not be impacted by test results.

Analysis of blood samples will be conducted in Immunovia's laboratory in Durham, NC by personnel who are blinded to subject data. Biomarker results will be analyzed using three predefined (locked) algorithm with predefined (locked) cut-offs resulting in a positive/negative test outcome.

Study Timeline

• Study Start: 2024-09-02
• Primary Completion: 2024-12-09
• Study Completion: 2025-01-06
• Status Verified: 2025-04
• Study First Submitted: 2025-04-11
• Study First Submitted QC: 2025-04-17
• Last Update Submitted: 2025-04-17
• Study First Posted: 2025-04-27
• Last Update Posted: 2025-04-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1066

Inclusion Criteria

• Informed consent available

• > 45 years of age

• PDAC cases

  • Treatment-naïve, pathologically confirmed PDAC Stage I or Stage II
  • Sporadic or familial/genetic PDAC

• Controls

  • Individuals at high risk for PDAC because of their familial and/or genetic history
  • Individuals with clinical symptoms/signs (e.g. abnormal imaging of the pancreas such as fullness, unexplained weight loss, etc) suggestive of PDAC who were found to NOT have PDAC based on clinical investigation (imaging evidence within 6 months of blood draw)
  • Controls will be selected to have similar demographic features (age/gender) to PDAC patients, as possible.

Exclusion Criteria

• Prior treatment for PDAC (i.e., prior resection, radiotherapy, or chemotherapy)

• Current immunosuppressive (e.g. systemic steroid therapy) or chemotherapy

• Major surgery or significant trauma within 12 weeks prior to blood sample collection

• Non-PDAC malignancies within 3 years prior to sample collection squamous or basal cell skin carcinoma is not an exclusion criteria)

• Control patients who currently have

  • biliary obstruction secondary to gallstones
  • prior diagnosis or imaging evidence of chronic pancreatitis
  • cystic pancreatic lesions >3.0 cm in diameter or showing worrisome features according to Fukuoka Consensus Guidelines.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Determine the sensitivity and specificity of IMMNOV-2 to differentiate serum samples from patients diagnosed with PDAC and controls.	Baseline

Secondary Outcome Measures

Name	Time	Method
Sensitivity and specificity of IMMNOV-2 compared to sensitivity and specificity of CA19-9 alone in patients age > or equal to 65 years old	Baseline
Sensitivity and specificity of IMMNOV-2 compared to sensitivity and specificity of CA19-9 alone in the overall population	Baseline
Sensitivity and specificity of IMMNOV-2 in patients age > or equal to 65 years of age	Baseline

Trial Locations

Locations (15)

HonorHealth Clinical Research Institute; 🇺🇸 Scottsdale, Arizona, United States

St. John's Cancer Institute; 🇺🇸 Burbank, California, United States

University of California San Diego; 🇺🇸 La Jolla, California, United States

Stanford Gastroenterology and Hepatology; 🇺🇸 Stanford, California, United States

University of Miami; 🇺🇸 Miami, Florida, United States

University of Chicago Medical Center; 🇺🇸 Chicago, Illinois, United States

Mount Sinai Hospital; 🇺🇸 New York, New York, United States

Oregon Health Sciences University; 🇺🇸 Portland, Oregon, United States

University of Pittsburgh Medical Center; 🇺🇸 Pittsburgh, Pennsylvania, United States

Regional One Health; 🇺🇸 Memphis, Tennessee, United States

Scroll for more (5 remaining)